IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the response to pomalidomide and dexamethasone in
relapse and refractory MM patients who are progressive and did not achieve at least a partial
response to bortezomib and lenalidomide. This study will determine the efficacy and toxicity
profile of 2 modalities of pomalidomide in patients with advanced myeloma, previously heavily
treated characterized with adverse prognostic and that are in desperate need of novel
therapeutics.